Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial

Respiratory Medicine

Volumn 104, Issue 5, 2010, Pages 668-674

  Richards, Duncan B ^a   Bareille, Philippe ^a   Lindo, Emma L ^a   Quinn, Dean ^b   Farrow, Stuart N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Bowen   (New Zealand)

Author keywords

Allergen challenge; Anti inflammatory; Asthma; PPAR ; Rosiglitazone

Indexed keywords

ADENOSINE PHOSPHATE; ALLERGEN; METHACHOLINE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; BRONCHOCONSTRICTING AGENT; METHACHOLINE CHLORIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOOT EDEMA; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INFLUENZA; INTERVENTION STUDY; MALE; MUSCLE SPASM; NERVOUSNESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; TACHYCARDIA; ADOLESCENT; AGONISTS; BLOOD; BREATH ANALYSIS; DIAGNOSTIC USE; IMMUNOLOGY; INHALATION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; YOUNG ADULT;

ADIPONECTIN; ADOLESCENT; ADULT; ALLERGENS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; NITRIC OXIDE; PPAR GAMMA; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 77951621270     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.11.006     Document Type: Article

References (30)

1. Martin G., Schoonjans K., Lefebvre A.M., Staels B., and Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 272 45 (1997) 28210-28217
2. Young P.W., Cawthorne M.A., Coyle P.J., Holder J.C., Holman G.D., Kozka I.J., et al. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT 4 as measured by photoaffinity labeling. Diabetes 44 (1995) 1087-1092
3. Benayoun L., Letuve S., Druilhe A., Boczkowski J., Dombret M.C., Mechighel P., Megret J., Leseche G., Aubier M., and Pretolani M. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med 164 8 Pt 1 (2001) 1487-1494
4. Belvisi M.G., and Hele D.J. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 134 1 (2008) 152-157
5. Spears M., Donnelly I., Jolly L., Brannigan M., Ito K., McSharry C., Lafferty J., Chaudhuri R., Braganza G., Bareille P., Sweeney L., Adcock I.M., Barnes P.J., Wood S., and Thomson N.C. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther 86 1 (2009) 49-53
6. Ward J.E., and Tan X. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. PPAR Res 2007 (2007) 14983
7. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., Libby P., and Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90 6 (2002) 703-710
8. Ueki S., Adachi T., Bourdeaux J., Oyamada H., Yamada Y., Hamada K., Kanda A., Kayaba H., and Chihara J. Expression of PPARgamma in eosinophils and its functional role in survival and chemotaxis. Immunol Lett 86 2 (2003) 183-189
9. Mueller C., Weaver V., Vanden Heuvel J.P., August A., and Cantorna M.T. Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys 418 2 (2003) 186-196
10. Woerly G., Honda K., Loyens M., Papin J.P., Auwerx J., Staels B., Capron M., and Dombrowicz D. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 198 3 (2003) 411-421
11. Trifilieff A., Bench A., Hanley M., Bayley D., Campbell E., and Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 139 1 (2003) 163-171
12. Hashimoto Y., and Nakahara K. Improvement of asthma after administration of pioglitazone. Diabetes Care 25 2 (2002) 401
13. Young P.W., Buckle D.R., Cantello B.C.C., Chapman H., Clapham J.C., Coyle P.J., et al. Identification of high-affinity binding sites for the insulin-sensitizer rosiglitazone (BRL 49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 284 (1998) 751-759
14. Seimandi M., Lemaire G., Pillon A., Perrin A., Carlavan I., Voegel J.J., Vignon F., Nicolas J.C., and Balaguer P. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 344 1 (2005) 8-15
15. Silvestri M., Oddera S., Sacco O., Balbo A., Crimi E., and Rossi G.A. Bronchial and bronchoalveolar inflammation in single early and dual responders after allergen inhalation challenge. Lungs 175 4 (1997) 277-285
16. Grzelewska-Rzymowska I., Gondorowicz K., Cieslewicz G., and Rozniecki J. Course of non-specific bronchial reactivity to histamine after bronchospasm induced by allergen challenge in patients with bronchial asthma. Pneumonol Alergol Pol 63 5-6 (1995) 273-280
17. Joos G.F., O'Connor B., Anderson S.D., Chung F., Cockcroft D.W., Dahlen B., DiMaria G., Foresi A., Hargreave F.E., Holgate S.T., Inman M., Lotvall J., Magnussen H., Polosa R., Postma D.S., and Riedler J. ERS Task Force. Indirect airway challenges. Eur Respir J 21 6 (2003) 1050-1068
18. van den Berge M., Kerstjens H.A., Meijer R.J., de Reus D.M., Koeter G.H., Kauffman H.F., and Postma D.S. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 164 7 (2001) 1127-1132
19. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., and Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 6 (2004) 2728-2735
20. Yang W.S., Jeng C.Y., Wu T.J., Tanaka S., Funahashi T., Matsuzawa Y., Wang J.P., Chen C.L., Tai T.Y., and Chuang L.M. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25 2 (2002) 376-380
21. Phillips L.S., Grunberger G., Miller E., Patwardhan R., Rappaport E.B., and Salzman A. Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24 2 (2001) 308-315
22. Kidney J.C., Boulet L.P., Hargreave F.E., et al. Evaluation of single-dose inhaled corticosteroid activity with an allergen challenge model. J Allergy Clin Immunol 100 (1997) 65-70
23. Palmqvist M., Bruce C., Sjostrand M., Arvidsson P., and Lotvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 60 (2005) 65-70
24. Singh D., Richards D., Knowles R.G., Schwartz S., Woodcock A., Langley S., and O'Connor B.J. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 176 10 (2007) 988-993
25. Alving K., Weitzberg E., and Lundberg J.M. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 6 (1993) 1368-1370
26. Kharitonov S.A., Yates D., Robbins R.A., et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343 (1994) 133-135
27. Hansel T.T., Erin E.M., and Barnes P.J. The allergen challenge. Clin Exp Allergy 32 2 (2002) 162-167
28. van Rensen E.L., Straathof K.C., Veselic-Charvat M.A., Zwinderman A.H., Bel E.H., and Sterk P.J. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 54 5 (1999 May) 403-408
29. Crosby M.B., Svenson J.L., Zhang J., Nicol C.J., Gonzalez F.J., and Gilkeson G.S. Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J Pharmacol Exp Ther 312 1 (2005) 69-76
30. Thomson N.C., Shepherd M., Spears M., and Chaudhuri R. Corticosteroid insensitivity in smokers with asthma: clinical evidence, mechanisms, and management. Treat Respir Med 5 6 (2006) 467-481